Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

Filter conferences

5th NASH Summit 2021

5th NASH Summit 2021


Date of beginning

Monday, 29 November 2021


4 days




Kaltrina Kastrati


This email address is being protected from spambots. You need JavaScript enabled to view it.


Masterfully combining the hottest insights on NASH from 65+ strong speaker faculty, including 45+ brand new speakers from the FDA, EMA, Takeda, Eli Lilly, Gilead, Pfizer, AstraZeneca, Ionis, Novo Nordisk and more, the 5th NASH Summit is your best opportunity to unite with fellow NASH drug developers to gain critical updates on the trailblazing research you need to meaningfully reassess your therapeutic approach and optimize your pipeline strategy for the future. Date and Time: On Monday November 29, 2021 at 10:00 am (ends Thursday December 02, 2021 at 3:30 pm) Prices: FULL ACCESS PASS: 2 Day Conference + 2 Workshops AND Seminar Day - Drug Developer: USD 3495.00,2 Day Conference + 1 Workshop + Seminar Day - Drug Developer: USD 3146.00,2 Day Conference + 2 Workshops OR Seminar Day - Drug Developer: USD 2797.00,2 Day Conference + 1 Workshop - Drug Developer: USD 2448.00,2 Day Conference Only - Drug Developer: USD 2099.00 URLs: Tickets: Brochure: Speakers: Christopher Jones Director of Biology Terns Pharmaceuticals, Elias Papatheodoru Chief Executive Officer Genkyotex, Maurizio Bonacini MD, AGAF Mission Gastroenterology and Hepatology, Richard Peneck Executive Director of Clinical Science Metacrine, Pnina Fishman Chief Executive Officer CanFite, Scott Harris Chief Medical Officer Altimmune, Susan Long Scientist Aligos Therapeutics, Winston Dunn Transplant Hepatologist University of Kansas Medical Center, Ashwani Singal Associate Professor of Medicine University of South Dakota Sanford, Francois Briand Director of Research and Business Development Physiogenex, Paul Monga Assistant Dean, Vice Chair and Endowed Chair of Experimental Pathology University of Pittsburgh, Pol Boudes Chief Medical Officer Galectin Therapeutics, Davide Povero Assistant Professor in Biochemistry and Molecular Biology Mayo Clinic, Melissa Miller Director of Human Genetics Pfizer, Pietro Scalfaro Chief Medical Officer Enyo Pharma, Stefano Romeo Professor in Molecular and Clinical Medicine University of Gothenburg, Becky Taub Founder, Director, CEO and President Madrigal Pharmaceuticals, David Moller Chief Scientific Officer Poxel Pharma, Markus Mayer Vice President of R&D Alentis, Stephen Rossi Chief Development Officer Northsea Therapeutics, Erik Tillman Principal Scientist Akero Therapeutics, Jordyn Tarazi Director of Investor Relations CohBar, Kenneth Cusi Professor of Medicine and Chief, Division of Endocrinology Diabetes and Metabolism, The University of Florida, Yury Popov Division of Gastroenterology, Hepatology and Nutrition Harvard Medical School, Archana Vijaykumar Senior Research Scientist Gilead Sciences, Banu Cole Scientific Director HemoShear Therapeutics, Inc., Pejman Soroosh Director of Scientific Obesity and Metabolic Disorders Janssen, Ryan Feaver Program Director HemoShear Therapeutics, Inc., George Makar Medical Officer Food and Drug Administration, Reshma Shringarpure Vice President of Clinical Research Akero Therapeutics, Richard Lee Executive Director Ionis Pharmaceuticals, Yanet Adere NASH Medical Science Liaison Novo Nordisk, Barry Crittenden Executive Director, Clinical Research Terns Pharmaceuticals, Hannah K. Drescher Postdoctoral Research Fellow at Gastrointestinal Unit Harvard Medical School, Liat Hayardeny Chief Scientific Officer Galmed Pharmaceuticals, Sophia Cazanve Chief Scientific Officer Glympse Bio, Bart Staels Professor University of Lille, Dr. Erin Quirk President and Chief Medical Officer Terns Pharmaceuticals, Marie O’Farrell Vice President of Research and Development Sagimet, Rhianna Laker Scientist AstraZeneca, Andrew Billin Senior Director - Biomarker Sciences Gilead, Cynthia Arbeeny Chief Scientific Officer Mitotherapeutix, Eduardo Martins Chief Medical Officer Sagimet Biosciences, James Trevaskis Senior Director of Biology and Head of Fibrosis Research Gilead, Ariel Feldstein Professor University of California San Diego, Axel Haupt Vice President for Diabetes Clinical Investigation and Insulin and Incretin Research Eli Lilly, Christian Meyer Global Director of Scientific Affairs, Diabetes and Metabolism Merck, Roberto Calle Executive Director Pfizer, Daniel Lindén Senior Principal Scientist AstraZeneca, Nikolaos Perakakis Professor of Metabolic and Vascular Medicine, Carl Gustav Carus Faculty of Medicine TU University of Dresden, Sharat Varma Principal Scientist Novo Nordisk, William Esler Senior Director Pfizer, Alessandro Pocai Senior Director for Cardiovascular and Metabolic Research Janssen, Detlef Schuppan Professor University Medical Center of the Johannes Gutenberg University, Quin Wills Cofounder and Chief Scientific Officer Ochre Bio, Ramy Younes Hepatologist and Clinical Program Leader NASH/Metabolism Boehringer Ingelheim, Gerardo Rodriguez Senior Medical Director Inventiva Phama, James E Brown DVM DURECT Corporation, Jeff McIntyre Advocate for Public Health, Public Policy and The Public Interest Global Liver, Joachim Musaeus EMA Product Lead/Deputy Head of Rheumatology, Gastroenterology and Immunology European Medicines Agency, Amy Articolo Medical Director NASH Novo Nordisk, Dr. Adrian M. Di Bisceglie Chief Medical Officer HighTide Therapeutics, Kendra Bence Executive Director Pfizer, Michael Cooreman Chief Medical Officer Inventiva Pharma, Abbas Bandukwala Science Policy Analyst, Biomarker Qualification Program FDA, Chandra Saravan Director of Discovery and Investigative Safety Novartis, Juliette Chen Director – Global Evidence and Outcomes Takeda, Tania Kamphaus NIMBLE Program Officer and Metabolic Diseases Program Lead Foundation for NIH